HOVON 150 AML
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
- NCT03839771 ↗
- Active, not recruiting
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on HOVON 150 AML (ivosidenib; enasidenib in IDH1/IDH2-mutated acute myeloid leukemia or myelodysplastic syndrome EB2) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HOVON 150 AML so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X | |
| 1 YouTube video | |
| 1 post on Bluesky |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy.
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
- Interventions
- AG-120; Placebo for AG-120; AG-221; Placebo for AG-221
- Arms
- Arm A: Placebo · Placebo comparator
- Arm B: Ivosidenib (IDH1) or Enasidenib (IDH2) · Experimental
- Enrollment
- 968 (estimated)
- Primary outcomes
- Event-free survival (EFS)
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland with University of Ulm
- Start
- Mar 1, 2019
- Primary completion
- Apr 17, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03839771 · updated Sep 22, 2026